This episode examines the explosive popularity of the diabetes drug Ozempic for off-label use as a weight loss injection. It contrasts skeptical perspectives on this trend from celebrities like Rob Lowe with enthusiastic endorsements from stars such as Kelly Osbourne. Additionally, it delves into the massive unregulated gray market for Ozempic that has emerged in China among its hundreds of millions of overweight and obese citizens, fueled by social media influencers and e-commerce. With domestic and global demand skyrocketing, the piece explores issues around patent protections, supply shortages, the rush to develop lower-potency generic alternatives, and the overall controversy inherent to using medicines intended for chronic illness as cosmetic aids.